CJC-1295 No DAC

CJC-1295 No DAC, also referred to in research literature as Modified GRF (1-29), is a synthetic peptide analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH). The "No DAC" designation indicates the absence of the Drug Affinity Complex modification, a structural feature associated in the literature with a comparatively shorter circulating duration relative to the DAC-conjugated form. It is supplied as a lyophilized powder for laboratory and professional research applications. This compound is not approved by the FDA for therapeutic use and is provided strictly for research and professional reference purposes. It is most often examined in the broader context of the growth hormone and somatotropic axis, frequently in conjunction with growth hormone secretagogue peptides in published experimental work. Individual results vary, and no clinical outcome is implied by inclusion in this catalog.

• Investigated in preclinical literature for its interaction with the growth hormone-releasing hormone (GHRH) receptor and pulsatile growth hormone signaling
• Studied in research settings for its reported influence on endogenous growth hormone secretion patterns
• Examined in experimental models exploring the somatotropic (GH/IGF-1) axis
• Referenced in research investigating short-acting GHRH analogs alongside growth hormone secretagogues
• Used as a comparator or reference peptide in laboratory studies of GHRH-receptor pharmacology

For research handling reference: the lyophilized peptide is typically reconstituted with bacteriostatic water (or another sterile diluent selected by the laboratory) added gently against the vial wall, with swirling rather than vigorous shaking to support peptide integrity. Unreconstituted vials are generally stored frozen and protected from light and moisture; once reconstituted, the solution is commonly kept refrigerated (approximately 2-8 C), shielded from light, and used within a limited window consistent with standard peptide-stability practice. Repeated freeze-thaw cycles and exposure to excessive heat or direct light are generally avoided. This information is provided solely as storage and handling reference; all clinical and research protocols, including any preparation, concentration, and use decisions, are determined solely by the licensed ordering provider, and this content is reference information only and is not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published research literature, CJC-1295 No DAC is described as a GHRH analog that binds to growth hormone-releasing hormone receptors on somatotroph cells of the anterior pituitary. Receptor engagement is reported in preclinical work to be associated with the synthesis and release of endogenous growth hormone in a manner described as preserving the natural pulsatile pattern of secretion. Amino acid substitutions relative to native GRF (1-29) are described as increasing resistance to enzymatic degradation, while the absence of the DAC moiety is associated with a shorter circulating duration than the DAC-modified variant. Downstream signaling through the growth hormone and IGF-1 pathway is described in the literature as the proposed basis for research interest in this compound. These mechanisms are derived from experimental and preclinical sources; individual results vary, and no therapeutic effect is established or implied.